VIR_logo_large_color.jpg
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
29 août 2023 16h30 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
03 août 2023 16h05 HE | Vir Biotechnology, Inc.
– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 – – Increased focus on proprietary antibody platform and discontinuation of...
VIR_logo_large.jpg
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
20 juil. 2023 08h00 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
05 juin 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
04 mai 2023 16h05 HE | Vir Biotechnology, Inc.
– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza – – Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
03 mai 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, May 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at...